Isomorphic Labs and MSD Partner on AI Oncology Drug Discovery

Isomorphic Labs announced on November 19, 2026, a strategic research collaboration with MSD to discover small-molecule oncology drug candidates, combining its AI drug-design engine with selected proprietary datasets and discovery expertise from the pharmaceutical company. MSD is the trade name used by Merck & Co., Inc., outside the United States and Canada. The partners will work against an oncology target they describe as strategically important. The announcement concerns early discovery work…

This article has been indexed from Unite.AI